| Literature DB >> 28366484 |
Sheenal V Patel1, David A Khan2.
Abstract
Biologic therapies are emerging as a significant therapeutic option for many with debilitating inflammatory and autoimmune conditions. As expansion in the number of FDA-approved agents continue to be seen, more unanticipated adverse reactions are likely to occur. Currently, the diagnostic tools, including skin testing and in vitro testing, to evaluate for immediate hypersensitivity reactions are insufficient. In this review, management strategies for common acute infusion reactions, injection site reactions, and immediate reactions suggestive of IgE-mediated mechanisms are discussed. Desensitization can be considered for reactions suggestive of IgE-mediated mechanisms, but allergists/immunologists should be involved in managing these patients.Entities:
Keywords: Biologic agents; Delayed reaction; Drug desensitization; Infusion reaction; Monoclonal antibodies; Omalizumab; Rituximab
Mesh:
Substances:
Year: 2017 PMID: 28366484 DOI: 10.1016/j.iac.2017.01.012
Source DB: PubMed Journal: Immunol Allergy Clin North Am ISSN: 0889-8561 Impact factor: 3.479